We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Valeant Pharmaceuticals announced that it reached an agreement to sell all of its outstanding equity interests in its Dendreon cancer business to Chinese conglomerate Sanpower Group for $820 million in cash.